Cargando…

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment

Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chavda, Vivek P., Gajjar, Normi, Shah, Nirav, Dave, Divyang J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Masson SAS. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532500/ https://www.ncbi.nlm.nih.gov/pubmed/36575695 http://dx.doi.org/10.1016/j.ejmcr.2021.100013

Ejemplares similares

2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update
por: Huang, Zoufang, et al.
Publicado: (2022)

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
por: Fenley, Juliana de C., et al.
Publicado: (2022)

Repurposing Anti-Cancer Drugs for COVID-19 Treatment
por: Borcherding, Nicholas, et al.
Publicado: (2020)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment
por: Kumar, Asit, et al.
Publicado: (2022)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
por: Dobroszycki, Joanna, et al.
Publicado: (2011)

Higher plasma drug levels in elderly people living with HIV treated with darunavir
por: Tyrberg, Erika, et al.
Publicado: (2021)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Drug repurposing for the treatment of COVID-19
por: Kato, Yuri, et al.
Publicado: (2022)

Repurposing drugs for treatment of COVID-19
por: Venkatesan, Priya
Publicado: (2021)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Correction: Higher plasma drug levels in elderly people living with HIV treated with darunavir
Publicado: (2021)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

Repurposing Existing Drugs for the Treatment of COVID-19
por: Farne, Hugo, et al.
Publicado: (2020)

Repurposed GI Drugs in the Treatment of COVID-19
por: Aguila, Enrik John T., et al.
Publicado: (2020)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir
por: Yu, Yuqi, et al.
Publicado: (2015)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data
por: Daskapan, Alper, et al.
Publicado: (2019)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
por: Parvathaneni, Vineela, et al.
Publicado: (2020)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
por: Uckun, Fatih M., et al.
Publicado: (2021)

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
por: Martinez, Miguel Angel
Publicado: (2021)

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
por: Martinez, Miguel Angel
Publicado: (2021)

An Overview of Repurposed Drugs for Potential COVID-19 Treatment
por: Govender, Kamini, et al.
Publicado: (2022)

Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update
por: Chavda, Vivek P, et al.
Publicado: (2022)

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nfdim9iqoia4mag8g6205e73n1